08:06 AM EDT, 04/01/2025 (MT Newswires) -- Pharvaris ( PHVS ) said Tuesday the European Commission has offered orphan designation to deucrictibant, the company's investigational drug to treat bradykinin-mediated angioedema.
In March 2022, deucrictibant received the US Food and Drug Administration's orphan drug designation to treat bradykinin-mediated angioedema, the company said.